, UNAIDS Global HIV & AIDS statistics-2018 fact sheet

F. J. Palella, K. M. Delaney, A. C. Moorman, M. O. Loveless, J. Fuhrer et al., Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection, N Engl J Med, vol.338, issue.13, pp.853-860, 1998.

M. S. Cohen, Y. Q. Chen, M. Mccauley, T. Gamble, M. C. Hosseinipour et al., Prevention of HIV-1 infection with early antiretroviral therapy, N Engl J Med, vol.365, issue.6, pp.493-505, 2011.

J. Troya and J. Bascuñana, Safety and Tolerability: Current Challenges to Antiretroviral Therapy for the Long-Term Management of HIV Infection, AIDS Rev, vol.18, issue.3, pp.127-137, 2016.

J. B. Nachega, V. C. Marconi, G. U. Van-zyl, E. M. Gardner, W. Preiser et al., HIV treatment adherence, drug resistance, virologic failure: evolving concepts, Infect Disord Drug Targets, vol.11, issue.2, pp.167-174, 2011.

J. Schouten, F. W. Wit, I. G. Stolte, N. A. Kootstra, M. Van-der-valk et al., Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGE h IV cohort study, Clin Infect Dis, vol.59, issue.12, pp.1787-1797, 2014.

R. A. Legarth, . Ahlströ-m-mg, G. Kronborg, C. S. Larsen, C. Pedersen et al., Long-Term Mortality in HIV-Infected Individuals 50 Years or Older: A Nationwide, Population-Based Cohort Study, J Acquir Immune Defic Syndr, vol.71, issue.2, pp.213-218, 2016.

D. Finzi, M. Hermankova, T. Pierson, L. M. Carruth, C. Buck et al., Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy, Science, vol.278, issue.5341, pp.1295-1300, 1997.

F. García, M. Plana, C. Vidal, A. Cruceta, W. A. O'brien et al., Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy, AIDS, vol.13, issue.11, pp.79-86, 1999.

B. S. Peters, The basis for HIV immunotherapeutic vaccines, Vaccine, vol.20, issue.5-6, pp.394-396, 2001.

V. H. Engelhard, Structure of peptides associated with MHC class I molecules, Curr Opin Immunol, vol.6, issue.1, pp.13-23, 1994.

O. Rötzschke and K. Falk, Origin, structure and motifs of naturally processed MHC class II ligands, Curr Opin Immunol, vol.6, issue.1, pp.45-51, 1994.

D. He, P. Kunwar, E. Eskin, H. Horton, P. Gilbert et al., Using HLA binding prediction algorithms for epitope mapping in HIV vaccine clinical trials, BCB '11 Proceedings of the 2nd ACM Conference on Bioinformatics, pp.594-601, 2011.

L. T. Da-silva, B. T. Santillo, A. De-almeida, A. Duarte, and T. M. Oshiro, Using Dendritic Cell-based immunotherapy to treat HIV: How can this strategy be improved? Front Immunol, vol.9, p.2993, 2018.

J. Banchereau and R. M. Steinman, Dendritic cells and the control of immunity, Nature, vol.392, issue.6673, pp.245-252, 1998.

A. Cobb, L. K. Roberts, A. K. Palucka, H. Mead, M. Montes et al., Development of a HIV-1 lipopeptide antigen pulsed therapeutic dendritic cell vaccine, J Immunol Methods, vol.365, issue.1-2, pp.27-37, 2011.

H. Gahé-ry-ségard, G. Pialoux, S. Figueiredo, C. Igé-a, M. Surenaud et al., Long-term specific immune responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine: characterization of CD8+-T-cell epitopes recognized, J Virol, vol.77, issue.20, pp.11220-11231, 2003.

H. Gahery, S. Figueiredo, C. Texier, S. Pouvelle-moratille, L. Ourth et al., HLA-DR-restricted peptides identified in the Nef protein can induce HIV type 1-specific IL-2/IFN-gamma-secreting CD4+ and CD4+ /CD8+ T cells in humans after lipopeptide vaccination, AIDS Res Hum Retroviruses, vol.23, issue.3, pp.427-437, 2007.
URL : https://hal.archives-ouvertes.fr/hal-00529938

D. Salmon-cé-ron, C. Durier, C. Desaint, L. Cuzin, M. Surenaud et al., Immunogenicity and safety of an HIV-1 lipopeptide vaccine in healthy adults: a phase 2 placebo-controlled ANRS trial, AIDS, vol.24, issue.14, pp.2211-2223, 2010.

Y. Lé-vy, R. Thié-baut, M. Montes, C. Lacabaratz, L. Sloan et al., Dendritic cell-based therapeutic vaccine elicits polyfunctional HIV-specific T-cell immunity associated with control of viral load, Eur J Immunol, vol.44, issue.9, pp.2802-2810, 2014.

K. K. Jensen, M. Andreatta, P. Marcatili, S. Buus, J. A. Greenbaum et al., Improved methods for predicting peptide binding affinity to MHC class II molecules, Immunology, vol.154, issue.3, pp.394-406, 2018.

M. Buggert, . Norströ-m-mm, C. Czarnecki, E. Tupin, M. Luo et al., Characterization of HIVspecific CD4+ T cell responses against peptides selected with broad population and pathogen coverage, PLoS One, vol.7, issue.7, p.39874, 2012.

M. Schieffer, H. K. Jessen, A. F. Oster, F. Pissani, D. Z. Soghoian et al., Induction of Gag-specific CD4 T cell responses during acute HIV infection is associated with improved viral control, J Virol, vol.88, issue.13, pp.7357-7366, 2014.

V. Pancré, N. Delhem, Y. Yazdanpanah, A. Delanoye, M. Delacre et al., Presence of HIV-1 Nef specific CD4 T cell response is associated with non-progression in HIV-1 infection, Vaccine, vol.25, issue.31, pp.5927-5937, 2007.

O. D. Solberg, S. J. Mack, A. K. Lancaster, R. M. Single, Y. Tsai et al., Balancing selection and heterogeneity across the classical human leukocyte antigen loci: a meta-analytic review of 497 population studies, Hum Immunol, vol.69, issue.7, pp.443-464, 2008.

F. A. Castelli, N. Szely, A. Olivain, N. Casartelli, C. Grygar et al., Hierarchy of CD4 T cell epitopes of the ANRS Lipo5 synthetic vaccine relies on the frequencies of pre-existing peptide-specific T cells in healthy donors, J Immunol, vol.190, issue.11, pp.5757-5763, 2013.
URL : https://hal.archives-ouvertes.fr/pasteur-01109463

S. Ranasinghe, S. Cutler, I. Davis, R. Lu, D. Z. Soghoian et al., Association of HLA-DRB1-restricted CD4 + T cell responses with HIV immune control, Nat Med, vol.19, issue.7, pp.930-933, 2013.

F. García, N. Climent, A. C. Guardo, C. Gil, and B. Leó-n-a,-autran, A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication, Sci Transl Med, vol.5, issue.166, pp.166-168, 2013.

J. M. Jacobson, J. P. Routy, S. Welles, M. Debenedette, I. Tcherepanova et al., Dendritic Cell Immunotherapy for HIV-1 Infection Using Autologous HIV-1 RNA: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, J Acquir Immune Defic Syndr, vol.72, issue.1, pp.31-38, 2016.

W. Yin, L. Gorvel, S. Zurawski, D. Li, L. Ni et al., Functional Specialty of CD40 and Dendritic Cell Surface Lectins for Exogenous Antigen Presentation to CD8(+) and CD4(+) T Cells, EBioMedicine, vol.5, pp.46-58, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01438516

A. L. Flamar, Y. Xue, S. M. Zurawski, M. Montes, B. King et al., Targeting concatenated HIV antigens to human CD40 expands a broad repertoire of multifunctional CD4+ and CD8+ T cells, AIDS, vol.27, issue.13, pp.2041-2051, 2013.

A. L. Flamar, H. Bonnabau, S. Zurawski, C. Lacabaratz, M. Montes et al., HIV-1 T cell epitopes targeted to Rhesus macaque CD40 and DCIR: A comparative study of prototype dendritic cell targeting therapeutic vaccine candidates, PLoS One, vol.13, issue.11, p.207794, 2018.

L. Cheng, Q. Wang, G. Li, R. Banga, J. Ma et al., TLR3 agonist and CD40-targeting vaccination induces immune responses and reduces HIV-1 reservoirs, J Clin Invest, vol.128, issue.10, pp.4387-4396, 2018.

G. Pantaleo and Y. Levy, Therapeutic vaccines and immunological intervention in HIV infection: a paradigm change, Curr Opin HIV AIDS, vol.11, issue.6, pp.576-584, 2016.